Holen Sie sich die Stockscreener-App
26.35
2.21%
0.57
Handel nachbörslich:
26.86
0.51
+1.94%
Schlusskurs vom Vortag:
$25.78
Offen:
$25.78
24-Stunden-Volumen:
494.80K
Relative Volume:
0.59
Marktkapitalisierung:
$1.46B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-131.12M
KGV:
-9.2681
EPS:
-2.8431
Netto-Cashflow:
$-112.73M
1W Leistung:
+7.73%
1M Leistung:
+2.09%
6M Leistung:
-30.66%
1J Leistung:
+156.32%
1-Tages-Spanne:
$25.14
$26.41
1-Wochen-Bereich:
$24.72
$26.41
52-Wochen-Spanne:
$9.732
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.35 | 1.43B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-10 | Eingeleitet | Mizuho | Outperform |
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
HighVista Strategies Sells Maze Therapeutics Shares in Q1 2026News and Statistics - IndexBox
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge - Intellectia AI
JP Morgan Maintains Maze Therapeutics (MAZE) Overweight Recommendation - MSN
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to Hold - MarketBeat
Rule 144 notice: MAZE (NASDAQ: MAZE) lists Common share lots and broker - Stock Titan
Janus Henderson (MAZE) discloses 2.86M shares, a 5.8% stake - Stock Titan
Maze Therapeutics stock falls despite strong phase 2 kidney drug data for MZE829 - MSN
MAZE Stock Price, Quote & Chart | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Maze Therapeutics files to sell 9.23M shares of common stock for holders - MSN
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo
[EFFECT] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline - TipRanks
LifeSci Capital Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Maze Therapeutics 1Q License Rev $20M >MAZE - Moomoo
Maze Therapeutics Expects Will Fund Ops Into 2029 Based on Its Current Business Plan >MAZE - Moomoo
Maze Therapeutics Inc. unveils quarterly results and updates on operational advances - Traders Union
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Maze Therapeutics 1Q Loss/Shr 45c >MAZE - Moomoo
Maze Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.45) — 10-Q Summary - TradingView
Maze Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Maze Therapeutics (NASDAQ: MAZE) trims Q1 loss as cash, pipeline and Shionogi milestone grow - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) Q1 2026 loss narrows on milestone revenue - Stock Titan
[POS AM] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - The Manila Times
What date does Maze Therapeutics, Inc.'s (MAZE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness - Yahoo Finance
TradingKey - TradingKey
Number of shareholders of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a Potential 149.49% Upside in Biotech - DirectorsTalk Interviews
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics (MAZE) CSBO exercises options for 14,305 shares - Stock Titan
Director Charles Homcy gifts 7,422 Maze Therapeutics (MAZE) shares - Stock Titan
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock - MarketBeat
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maze Therapeutics Inc-Aktie (MAZE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
May 14 '26 |
Option Exercise |
10.42 |
15,000 |
156,300 |
15,000 |
| Bernstein Harold | President, R&D & CMO |
May 14 '26 |
Sale |
26.22 |
15,000 |
393,354 |
0 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):